

## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/55

February 6, 2025

**To,**  
**The Listing Department**  
**National Stock Exchange of India Ltd**  
**Exchange Plaza, C-1, Block G,**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai – 400 051**

**To,**  
**The Listing Department**  
**BSE Limited**  
**Rotunda Building, Phiroze Jeejeebhoy**  
**Towers, Dalal Street, Fort, Mumbai –**  
**400 001**

**Symbol: AKUMS****Scrip Code: 544222****Sub: Outcome of Board Meeting held on 06th February, 2025.**


Respected Sir/Madam,

In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 6<sup>th</sup> February, 2025 has inter-alia considered and approved the following:

1. The Un-audited (Standalone & Consolidated) Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2024, along with the Limited Review Reports thereon, as received from the Statutory Auditors Walker Chandiook & Co. LLP, Chartered Accountants. Copies of such un-audited financial results along with the Limited Review Reports thereon are enclosed herewith as **Annexure-A**.
2. The board took note of the cessation of Mr. Nand Lal Kalra (DIN: 05268554), as an Independent Director of the company w.e.f 05.02.2025 due to attaining the age of 75 years. The company has intimated in detailed to the stock exchanges vide it's letter dated 05.02.2024 about the same with all the relevant annexures.

With the retirement of Mr. Nand Lal Kalra , below mentioned will be updated composition of the board committees:

Name of the committee	Composition after Reconstitution	Member / Chairman	Category
Audit Committee	Mr. Kewal Kundanlal Handa	Chairman	Non-Executive – Independent Director
	Ms. Matangi Gowrishankar	Member	Non-Executive – Independent Director
	Mr. Satwinder Singh	Member	Non-Executive – Independent Director
	Mr. Sunil Kumar Thakur	Member	Non-Executive Director



ISO 9001 : 2015  
 ISO 14001 : 2015  
 ISO 17025 : 2005 (NABL)

WHO-GMP  
 US : NSF  
 H A C C P



## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Nomination and Remuneration Committee	Ms. Matangi Gowrishankar	Chairman	Non-Executive – Independent Director
	Mr. Kewal Kundanlal Handa	Member	Non-Executive – Independent Director
	Mr. Sunil Kumar Thakur	Member	Non-Executive Director
	Mr. Satwinder Singh	Member	Non-Executive – Independent Director
Risk Management Committee	Mr. Sanjeev Jain	Chairman	Executive – Managing Director
	Mr. Sandeep Jain	Member	Executive – Managing Director
	Mr. Kewal Kundanlal Handa	Member	Non-Executive – Independent Director
	Ms. Matangi Gowrishankar	Member	Non-Executive – Independent Director
	Mr. Sumeet Sood	Member	CFO (Non Board Member)
Stakeholder Relationship Committee	Mr. Sanjeev Jain	Chairman	Executive – Managing Director
	Mr. Sandeep Jain	Member	Executive – Managing Director
	Mr. Satwinder Singh	Member	Non-Executive – Independent Director
Corporate Social Responsibility Committee	Mr. Sandeep Jain	Chairman	Executive – Managing Director
	Mr. Sanjeev Jain	Member	Executive – Managing Director
	Ms. Matangi Gowrishankar	Member	Non-Executive – Independent Director
	Mr. Sunil Kumar Thakur	Member	Non-Executive Director


3. The Postal Ballot Notice to obtain the approval of the shareholders for ratification and modification of Akums Employee Stock Option Scheme 2022 and ratification of extending benefits to the employees of subsidiaries.

Mr. Suresh Pandey (Membership No: 7776, COP No: 8529), Partner of M/s SPG & Associates, Company Secretaries, has been appointed as Scrutinizer to scrutinize the Postal Ballot's e-voting process and vote casted in fair and transparent manner.

4. To incorporate subsidiaries in Europe on each in United Kingdom and Malta with the objective to enhance its export business and to register dossiers in its own name.

Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as **Annexure-B**.

5. Setting up of R&D division in Mumbai with a tentative cost to be around INR 27 Crores, plus applicable government taxes and stamp duty. The Company will further invest INR 5.00 Cr. for set up, renovating, restructuring of the building.



ISO 9001 : 2015  
 ISO 14001 : 2015  
 ISO 17025 : 2005 (NABL)

WHO-GMP  
 US : NSF  
 H A C C P



**AKUMS DRUGS & PHARMACEUTICALS LIMITED**

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

---

6. Setting up two (2) Dry Powder Injection lines with a estimated cost of acquisition a land for manufacturing Dry Powder Injection is approximately INR 17.5 crores, plus applicable government taxes and stamp duty and additional investment of INR 30. Crores for setting up the manufacturing lines.

The Board Meeting commenced at 03:30 PM and concluded at 04:15 PM.

This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer



ISO 9001 : 2015  
ISO 14001 : 2015  
ISO 17025 : 2005 (NABL)

WHO-GMP  
US : NSF  
H A C C P



## Walker Chandniok &amp; Co LLP

---

Walker Chandniok & Co LLP  
L 41, Connaught Circus,  
Outer Circle,  
New Delhi - 110 001  
India  
T +91 11 45002219  
F +91 11 42787071

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Financial Results of the Company pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended)**

**To the Board of Directors of Akums Drugs and Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') (in which is included interim financial information of Akums Employee Benefit Trust ('ESOP Trust') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the quarter ended 31 December 2024 and year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). Attention is drawn to the fact that the figures for the corresponding quarter and year to date period ended 31 December 2023 have been approved by the Company's Board of Directors but have not been subjected to audit or review.
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above and the consideration of the review reports of the other auditor referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandniok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India.



# Walker ChandioK &Co LLP

## Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

5. We draw attention to Note 7 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department subsequent to quarter and nine-month period ended 31 December 2024, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. Further, the Company has not received any order/ notice/ communication on the findings of such investigation by the Income tax department till date. Accordingly, the impact of this matter for the quarter and nine-month period ended 31 December 2024 and the adjustments (if any) required, is presently not ascertainable. Our conclusion is not modified in respect of this matter.
6. The Statement includes the interim financial information of ESOP trust, which has not been reviewed, whose interim financial information reflects total revenues of ₹ 0.00 million and ₹ 0.00 million, total net profit after tax of ₹ 0.00 million and ₹ 0.00 million and total comprehensive income of ₹ 0.00 million and ₹ 0.00 million, for the quarter and year-to-date period ended on 31 December 2024, respectively, as considered in the Statement. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this ESOP trust, is based solely on such unreviewed financial information.

Our conclusion is not modified in respect of this matter with respect to our reliance on the aforesaid financial information certified by the Board of Directors.

7. We did not review the interim financial results of one Limited Liability Partnership Firm ('LLP') in which the Company has invested included in the Statement, where such interim financial results reflect Company's share of net profit (including other comprehensive income) of ₹ 10.68 million and ₹ 72.59 million for the quarter and nine-month period ended 31 December 2024, as considered in the Statement. Such interim financial results have been reviewed by the other auditor, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of the aforesaid LLP, is based solely on the review report of such other auditor.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and the report of the other auditor.

**For Walker ChandioK & Co LLP**  
Chartered Accountants  
Firm Registration No.: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No.: 507892  
UDIN: 25507892BMNSKN1512



**Place:** New Delhi  
**Date:** 06 February 2025

**Chartered Accountants**

Statement of unaudited standalone financial results for the quarter and nine months ended 31 December 2024

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31 Dec 2024	30 Sep 2024	31 Dec 2023	31 Dec 2024	31 Dec 2023	31 March 2024
		Unaudited	Unaudited	Unaudited (refer note 8 and 9)	Unaudited	Unaudited (refer note 9)	Audited
<b>I</b>	<b>Income</b>						
	Revenue from operations	3,374.07	3,283.49	3,831.53	9,830.31	11,457.65	14,441.19
	Other income	338.42	321.24	248.91	921.42	674.57	941.21
	<b>Total income (I)</b>	<b>3,712.49</b>	<b>3,604.73</b>	<b>4,080.44</b>	<b>10,751.73</b>	<b>12,132.22</b>	<b>15,382.40</b>
<b>II</b>	<b>Expenses</b>						
	Cost of materials consumed	2,066.24	1,964.68	2,420.93	6,039.95	6,967.04	8,672.35
	Changes in inventories of finished goods and work-in-progress	78.54	(60.71)	0.24	(103.99)	(66.58)	64.42
	Employee benefits expense	503.40	503.80	462.60	1,479.00	1,284.77	1,752.80
	Finance costs	22.94	41.83	48.41	126.83	135.18	183.13
	Depreciation and amortisation expense	106.83	93.87	83.11	294.52	236.08	326.94
	Fair value changes to financial instruments (refer note 5)	-	-	188.98	(38.67)	2,725.44	3,577.74
	Other expenses	385.63	445.06	441.60	1,246.27	1,208.23	1,640.46
	<b>Total expenses (II)</b>	<b>3,163.58</b>	<b>2,988.53</b>	<b>3,645.87</b>	<b>9,043.91</b>	<b>12,490.16</b>	<b>16,217.84</b>
<b>III</b>	<b>Profit/ (loss) before exceptional items and tax (I-II)</b>	<b>548.91</b>	<b>616.20</b>	<b>434.57</b>	<b>1,707.82</b>	<b>(357.94)</b>	<b>(835.44)</b>
<b>IV</b>	<b>Exceptional items</b>	-	-	-	-	(181.00)	(193.89)
<b>V</b>	<b>Profit/ (loss) before tax (III-IV)</b>	<b>548.91</b>	<b>616.20</b>	<b>434.57</b>	<b>1,707.82</b>	<b>(538.94)</b>	<b>(1,029.33)</b>
<b>VI</b>	<b>Tax expense</b>						
	Current tax						
	for current period	131.17	153.73	162.14	410.13	422.90	469.90
	for earlier years	(0.60)	4.50	-	3.90	13.50	13.50
	Deferred tax (credit)/ charge						
	for current period	6.66	(24.58)	(21.00)	(19.19)	100.49	141.78
	for earlier years	-	(21.11)	-	(21.11)	-	-
	<b>Total tax expense</b>	<b>137.23</b>	<b>112.54</b>	<b>141.14</b>	<b>373.73</b>	<b>536.89</b>	<b>625.18</b>
<b>VII</b>	<b>Profit/ (loss) for the period/ year (V-VI)</b>	<b>411.68</b>	<b>503.66</b>	<b>293.43</b>	<b>1,334.09</b>	<b>(1,075.83)</b>	<b>(1,654.51)</b>
<b>VIII</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified to statement of profit and loss						
	Re-measurement gains/(losses) on defined benefit plans	2.57	(5.83)	(28.98)	(0.19)	(31.74)	(29.07)
	Tax effect relating to these items	(0.64)	1.46	7.29	0.05	7.99	7.32
<b>IX</b>	<b>Total comprehensive income for the period/ year (VII+VIII) (comprising profit/ (loss) for the period/ year and other comprehensive income, net of tax)</b>	<b>413.61</b>	<b>499.29</b>	<b>271.74</b>	<b>1,333.95</b>	<b>(1,099.58)</b>	<b>(1,676.26)</b>
<b>X</b>	Paid-up share capital (net off shares held by ESOP trust) (refer note 11)	306.21	306.21	286.13	306.21	286.13	286.13
<b>XI</b>	Other equity						1,152.65
<b>XII</b>	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*						
	Basic and diluted	2.69	3.38	2.05	8.99	(7.52)	(11.56)

\*EPS for the quarters and nine months ended have not been annualised

*Sanjeev*

*Sanjeev*





**Notes:**

- The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 6 February 2025.
- These standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- These standalone financial results for quarter and nine months ended 31 December 2024 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any qualifications.
- The Company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share) and as a result the equity shares of the Company has been listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million. The Company has estimated ₹ 1,116.58 million as IPO related expenses and allocated such expenses between the Company (₹ 426.30 million has been adjusted to the securities premium account) and selling shareholders (₹ 690.28 million) in proportion to the equity shares allotted to the public as fresh issue by the Company and under the offer for sale by selling shareholders respectively. Out of the total IPO proceeds the funds available in public offer account is ₹ 513.14 million for remitting funds for pending IPO related expenses. The Company has received an amount of ₹ 6,373.70 million (net of IPO expenses of ₹ 426.30 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

Objects	Planned net proceeds as per prospectus	Actual net proceeds	Utilisation upto 31 December 2024	Unutilised amount as on 31 December 2024
Repayment/prepayment of all or certain borrowings of the Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of the Subsidiaries namely, Maxcure Nutraceuticals Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of the Company	550.00	550.00	-	550.00
Pursuing inorganic growth initiatives through acquisitions	278.70	278.70	-	278.70
General corporate purposes	1,675.00	1,675.00	1,675.00	-
<b>Total proceeds</b>	<b>6,373.70</b>	<b>6,373.70</b>	<b>5,545.00</b>	<b>828.70</b>

- The Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Company to buyback its equity shares at fair market value in case the Company and/ or its promoters were not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the standalone financial results of the Company which has been shown separately in the aforementioned standalone financial results. However, on 29 May 2024, the Investor has waived off these rights in entirety and post listing the Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these standalone financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from financial liabilities to other equity thereby increasing the net worth.
- The Company operates in only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segment is not applicable and accordingly not made.
- Subsequent to the quarter and nine-month period ended 31 December 2024, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company.

During the search and seizure proceedings, the Company has fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Company continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. The Company has not yet received any written order/ notice/ communication on the findings of such investigation from the department and accordingly there have been no demands which have been raised on the Company as of date. Based on the foregoing and having regard to the matters of the inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these unaudited standalone financial results for the quarter and nine months period ended 31 December 2024 in this regard.

- The figures for the quarter ended 31 December 2023 are the balancing figures between the management certified year to date figures upto the nine months period ended 31 December 2023 and audited year to date figures upto six months period ended 30 September 2023 extracted from the audited Special Purpose Standalone Interim Statement of Profit and loss for the six months period ended 30 September 2023.
- The standalone financial results for the quarter and nine months ended 31 December 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for this quarter and nine months provide a true and fair view of the Company's affairs.
- In order to repay the loans of the subsidiaries, which was part of object clause of the IPO as mentioned in note 4 above, during the quarter and nine months period ended 31 December 2024, the Company has made following investments in its wholly owned subsidiaries:

Name of company	Nature of investments	Quarter ended	Nine months ended
		31 Dec 2024	31 Dec 2024
Pure and Cure Healthcare Private Limited	0.01% Optionally Convertible Redeemable Preference Shares	2,020.90	2,020.90
Maxcure Nutraceuticals Limited	0.01% Optionally Convertible Redeemable Preference Shares	250.00	250.00

- The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Company.

For and on behalf of Board of Directors of  
Akums Drugs and Pharmaceuticals Limited



Sanjeev Jain  
Managing Director  
DIN: 00323433



Sandeep Jain  
Managing Director  
DIN: 00323476

Place: New Delhi  
Date: 6 February 2025



# Walker Chandiook & Co LLP

---

Walker Chandiook & Co LLP  
L 41, Connaught Circus,  
Outer Circle,  
New Delhi – 110 001  
India  
T +91 11 45002219  
F +91 11 42787071

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Akums Drugs and Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2024 and the consolidated year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). Attention is drawn to the fact that the consolidated figures for the corresponding quarter and year to date period ended 31 December 2023 as reported in the statement have been approved by the Holding Company's Board of Directors but have not been subjected to audit or review.
2. The Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

*(This space has been intentionally left blank.)*



---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India



# Walker Chandiook & Co LLP

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 8 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department subsequent to quarter and nine-month period ended 31 December 2024, at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. Further, the Group has not received any order/ notice/ communication on the findings of such investigation by the Income tax department till date. Accordingly, the impact of this matter for the quarter and nine-month period ended 31 December 2024 and the adjustments (if any) required, is presently not ascertainable. Our conclusion is not modified in respect of this matter.
6. We did not review the interim financial results of 7 subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 591.69 million and ₹ 1,660.15 million, total net loss after tax of ₹ 116.17 million and ₹ 368.10 million, total comprehensive loss of ₹ 116.68 million and ₹ 368.80 million for the quarter and year to date period ended 31 December 2024, as considered in the Statement. These financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.



*(This space has been intentionally left blank.)*

# Walker Chandiook & Co LLP

## Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

7. The Statement includes the interim financial information of Akums Employee Benefit Trust, included in the unaudited interim standalone financial results of the Holding Company, which has not been reviewed, whose interim financial information reflects total revenues of ₹ 0.00 million and ₹ 0.00 million, total net profit of ₹ 0.00 million and ₹ 0.00 million and total comprehensive income of ₹ 0.00 million and ₹ 0.00 million, for the quarter and year to date period ended on 31 December 2024, respectively, as considered in the Statement and as considered in the unaudited interim standalone financial results of Holding Company included in the Group. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this ESOP trust are solely based on such unreviewed interim financial information.

Our conclusion is not modified in respect of this matter with respect to our reliance on the aforesaid financial information certified by the Board of Directors.

**For Walker Chandiook & Co LLP**  
Chartered Accountants  
Firm Registration No.: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No.: 507892  
UDIN: 25507892BMNSKM9533



**Place:** New Delhi  
**Date:** 06 February 2025

# Walker Chandiook & Co LLP

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)**

## **Annexure 1**

### **List of entities included in the Statement**

1. Pure and Cure Healthcare Private Limited
2. Malik Lifesciences Private Limited
3. Maxcure Nutravedics Limited
4. Unosource Pharma Limited
5. Akumentis Healthcare Limited
6. Sarvagunaushdhi Private Limited
7. Planteous Pharmaceuticals Limited
8. Upadriish Researchem LLP
9. Nicholas Healthcare Limited
10. Akums Healthcare Limited
11. Qualymed Pharma Private Limited
12. Amazing Research Laboratories Limited\*
13. May and Baker Pharmaceuticals Limited\*
14. Burroughs Welcome Pharmacia Private Limited\*
15. Akums Employee Benefit Trust (w.e.f. 12 April 2024)

### **Step Down Subsidiary**

1. Medibox Pharma Limited (subsidiary of Maxcure Nutravedics Limited)

\*Hived off w.e.f. 01 April 2024



**Chartered Accountants**



**Akums Drugs and Pharmaceuticals Limited**  
 Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034  
 CIN: L24239DL2004PLC125888

Email Id: es@akums.net; Website: www.akums.in

**Statement of unaudited consolidated financial results for the quarter and nine months period ended 31 December 2024**

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
		Unaudited	Unaudited	Unaudited (refer note 9 and 10)	Unaudited	Unaudited (refer note 10)	Audited
<b>I</b>	<b>Income</b>						
	Revenue from operations	10,104.11	10,330.87	10,828.35	30,626.11	32,339.73	41,781.82
	Other income	145.61	134.70	89.16	345.77	237.84	340.25
	<b>Total income</b>	<b>10,249.72</b>	<b>10,465.57</b>	<b>10,917.51</b>	<b>30,971.88</b>	<b>32,577.57</b>	<b>42,122.07</b>
<b>II</b>	<b>Expenses</b>						
	Cost of materials consumed	5,645.98	5,056.69	5,819.78	16,297.63	17,650.71	22,783.70
	Purchase of stock-in-trade	302.72	908.56	951.02	1,619.83	1,960.39	2,595.27
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	75.23	(5.73)	86.17	26.02	198.12	123.40
	Employee benefits expense	1,755.98	1,801.03	1,624.84	5,319.24	4,829.10	6,468.64
	Finance costs	51.34	119.03	124.37	300.58	382.37	506.14
	Depreciation and amortisation expense	445.20	348.65	315.49	1,134.49	916.87	1,256.40
	Fair value changes to financial instruments (refer note 6)	-	-	188.98	(38.67)	2,725.44	3,577.74
	Other expenses	1,110.55	1,358.47	1,223.23	3,696.39	3,776.01	5,003.22
	<b>Total expenses</b>	<b>9,387.00</b>	<b>9,586.70</b>	<b>10,333.88</b>	<b>28,355.51</b>	<b>32,439.01</b>	<b>42,314.51</b>
<b>III</b>	<b>Profit/ (loss) before exceptional items and tax (I-II)</b>	<b>862.72</b>	<b>878.87</b>	<b>583.63</b>	<b>2,616.37</b>	<b>138.56</b>	<b>(192.44)</b>
	Exceptional items (refer note 7)	(47.81)	(36.99)	(9.15)	(84.80)	262.51	260.34
<b>IV</b>	<b>Profit/ (loss) before tax for the period/ year</b>	<b>910.53</b>	<b>915.86</b>	<b>592.78</b>	<b>2,701.17</b>	<b>(123.95)</b>	<b>(452.78)</b>
<b>V</b>	<b>Tax expense</b>						
	Current tax						
	for current period	205.77	233.54	60.43	626.86	659.07	740.25
	for earlier years	(18.32)	7.02	(0.03)	(11.30)	15.50	15.18
	Deferred tax charge/ (credit)						
	for current period	49.46	29.90	(34.81)	154.51	181.68	166.67
	for earlier years	10.50	(21.11)	-	(10.61)	-	-
	Adjustment on account of merger :-						
	Income-tax for earlier years	-	-	(182.90)	-	(182.90)	(182.90)
	Deferred tax (credit)	-	-	(1,199.88)	-	(1,199.88)	(1,199.88)
	<b>Total tax expense</b>	<b>247.41</b>	<b>249.35</b>	<b>(1,357.19)</b>	<b>759.46</b>	<b>(526.53)</b>	<b>(460.68)</b>
<b>VI</b>	<b>Profit for the period/ year (IV-V)</b>	<b>663.12</b>	<b>666.51</b>	<b>1,949.97</b>	<b>1,941.71</b>	<b>402.58</b>	<b>7.90</b>
<b>VII</b>	<b>Other comprehensive income</b>						
	- Items that will not be reclassified to profit and loss	2.48	(11.51)	(49.87)	(1.07)	(55.92)	(50.50)
	- income-tax on items that will not be reclassified to profit and loss	(0.79)	2.74	13.31	0.28	15.35	13.72
	<b>Other comprehensive income, net of tax</b>	<b>1.69</b>	<b>(8.77)</b>	<b>(36.56)</b>	<b>(0.79)</b>	<b>(40.57)</b>	<b>(36.78)</b>
<b>VIII</b>	<b>Total comprehensive income for the period/ year (VI+VII) (comprising profit/ (loss) for the period/ year and other comprehensive income, net of tax)</b>	<b>664.81</b>	<b>657.74</b>	<b>1,913.41</b>	<b>1,940.92</b>	<b>362.01</b>	<b>(28.88)</b>
<b>IX</b>	<b>Profit/ (loss) for the period/ year attributable to:</b>						
	Owners of the Parent	651.82	652.06	1,937.02	1,905.59	372.85	(40.35)
	Non controlling interest	11.30	14.45	12.95	36.12	29.73	48.25
<b>X</b>	<b>Other comprehensive income for the period/ year attributable to:</b>						
	Owners of the Parent	1.82	(8.94)	(36.45)	(0.82)	(40.32)	(36.56)
	Non controlling interest	(0.13)	0.17	(0.11)	0.03	(0.25)	(0.22)
<b>XI</b>	<b>Total comprehensive income for the period/ year attributable to:</b>						
	Owners of the Parent	653.64	643.12	1,900.57	1,904.77	332.53	(76.91)
	Non controlling interest	11.17	14.62	12.84	36.15	29.48	48.03
<b>XII</b>	Paid-up share capital (net off shares held by ESOP trust) (refer note 5)	306.21	306.21	286.13	306.21	286.13	286.13
<b>XIII</b>	Other equity						6,808.85
<b>XIV</b>	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*	4.26	4.37	13.21	12.84	2.61	(0.28)

\*EPS for the quarters and nine months period ended have not been annualised

*Amrisha*

*Sameer*



**UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES**

The Group is primarily engaged in three business segments a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (API) and c) Branded and Generic formulations. Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith :

(₹ in million, unless otherwise stated)

Particulars	Quarter ended			Nine months period ended		Year ended
	31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
	Unaudited	Unaudited	Unaudited (refer note 9 and 10)	Unaudited	Unaudited (refer note 10)	Audited
<b>I. Revenue from operations (including inter-segment)</b>						
a) CDMO	8,430.41	8,553.39	9,465.61	25,394.85	28,206.02	36,196.32
b) API	477.88	808.38	753.15	2,105.11	2,044.25	2,784.29
c) Branded and generic formulations	1,829.32	1,750.33	1,735.17	5,253.82	5,508.90	6,995.40
	<b>10,737.61</b>	<b>11,112.10</b>	<b>11,953.93</b>	<b>32,753.78</b>	<b>35,759.17</b>	<b>45,976.01</b>
<b>II. Revenue from operations (external customers)</b>						
a) CDMO	7,874.42	7,986.57	8,541.70	23,681.16	25,347.68	32,663.48
b) API	400.56	594.10	551.52	1,691.52	1,484.94	2,125.16
c) Branded and generic formulations	1,829.13	1,750.20	1,735.13	5,253.43	5,507.11	6,993.18
<b>Revenue from operations</b>	<b>10,104.11</b>	<b>10,330.87</b>	<b>10,828.35</b>	<b>30,626.11</b>	<b>32,339.73</b>	<b>41,781.82</b>

Particulars	Quarter ended			Nine months ended		Year ended
	31 December 2024	30 September 2024	31 December 2023	31 December 2024	31 December 2023	31 March 2024
	Unaudited	Unaudited	Unaudited (refer note 9 and 10)	Unaudited	Unaudited (refer note 10)	Audited
<b>III. Segment results before depreciation*</b>						
a) CDMO	1,213.61	1,227.13	1,111.18	3,652.28	4,061.57	4,866.92
b) API	(108.94)	(142.85)	(164.82)	(373.39)	(375.30)	(455.14)
c) Branded and generic formulations	197.89	180.06	238.72	549.11	395.76	590.58
<b>IV. Segment results**</b>						
a) CDMO	879.66	945.49	860.63	2,762.41	3,351.08	3,886.14
b) API	(210.48)	(214.52)	(236.15)	(617.67)	(586.77)	(736.53)
c) Branded and generic formulations	173.06	168.30	223.98	500.36	343.08	525.88
<b>Sub total</b>	<b>842.24</b>	<b>899.27</b>	<b>848.46</b>	<b>2,645.10</b>	<b>3,107.39</b>	<b>3,675.49</b>
Unallocated corporate income/ (expenses) [net]	2.11	2.09	(186.84)	44.98	(2,719.15)	(3,552.23)
Interest income	54.62	80.02	29.22	178.48	78.88	120.00
Finance costs	(36.25)	(102.51)	(107.21)	(252.19)	(328.56)	(435.70)
<b>Profit/ (loss) before exceptional items and tax</b>	<b>862.72</b>	<b>878.87</b>	<b>583.63</b>	<b>2,616.37</b>	<b>138.56</b>	<b>(192.44)</b>
Exceptional items	(47.81)	(36.99)	(9.15)	(84.80)	262.51	260.34
<b>Profit/ (loss) before tax</b>	<b>910.53</b>	<b>915.86</b>	<b>592.78</b>	<b>2,701.17</b>	<b>(123.95)</b>	<b>(452.78)</b>
Tax expenses	247.41	249.35	(1,357.19)	759.46	(526.53)	(460.68)
<b>Profit for the period/ year</b>	<b>663.12</b>	<b>666.51</b>	<b>1,949.97</b>	<b>1,941.71</b>	<b>402.58</b>	<b>7.90</b>
<b>V. Segment assets</b>						
a) CDMO	27,918.56	27,166.62	26,703.58	27,918.56	26,703.58	24,318.00
b) API	4,372.27	4,574.28	4,910.84	4,372.27	4,910.84	4,680.03
c) Branded and generic formulations	2,494.18	2,495.02	3,118.53	2,494.18	3,118.53	2,825.96
Less :- Inter-segment eliminations	(819.99)	(747.36)	(1,505.78)	(819.99)	(1,505.78)	(783.76)
<b>Segment assets</b>	<b>33,965.02</b>	<b>33,488.56</b>	<b>33,227.17</b>	<b>33,965.02</b>	<b>33,227.17</b>	<b>31,040.23</b>
Un-allocated corporate assets	4,697.69	9,215.47	4,356.68	4,697.69	4,356.68	4,123.42
<b>Total assets</b>	<b>38,662.71</b>	<b>42,704.03</b>	<b>37,583.85</b>	<b>38,662.71</b>	<b>37,583.85</b>	<b>35,163.65</b>
<b>VI. Segment liabilities</b>						
a) CDMO	6,824.46	6,708.04	8,638.95	6,824.46	8,638.95	7,401.31
b) API	351.87	395.17	1,049.96	351.87	1,049.96	423.63
c) Branded and generic formulations	2,272.88	2,306.84	2,531.83	2,272.88	2,531.83	2,226.73
Less :- Inter-segment eliminations	(819.99)	(747.36)	(1,505.78)	(819.99)	(1,505.78)	(783.76)
<b>Segment liabilities</b>	<b>8,629.22</b>	<b>8,662.69</b>	<b>10,714.96</b>	<b>8,629.22</b>	<b>10,714.96</b>	<b>9,267.91</b>
Un-allocated corporate liabilities	898.89	5,571.57	19,273.13	898.89	19,273.13	18,690.88
<b>Total liabilities</b>	<b>9,528.11</b>	<b>14,234.26</b>	<b>29,988.09</b>	<b>9,528.11</b>	<b>29,988.09</b>	<b>27,958.79</b>

\* Segment results before depreciation is calculated as the sum of profit/ (loss) before tax, exceptional items, finance costs, fair value changes to financial instruments and depreciation and amortisation expense.

\*\* Segment results is calculated as segment results before depreciation less finance costs pertaining to segments and depreciation and amortisation expense.

*Sanjay*  
*Sanjay*





**Notes :**

- The above consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 06 February 2025.
- The above consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding company' or 'Parent'), together with its subsidiaries (collectively the 'Group') have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).
- These consolidated financial results for quarter and nine months period ended 31 December 2024 have been subjected to limited review by the statutory auditors of the Holding Company. The limited review report does not contain any qualifications.
- The Holding Company has completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of ₹ 2 each at an issue price of ₹ 679 per share (including share premium of ₹ 677 per share) and as a result the equity shares of the Holding Company has been listed on National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity shares aggregating to ₹ 6,800.00 million and offer for sale of 17,330,435 equity shares by selling shareholders, aggregating to ₹ 11,767.37 million.  
The Holding Company has estimated ₹ 1,116.58 million as IPO related expenses and allocated such expenses between the Holding Company (₹ 426.30 million has been adjusted to the securities premium account) and selling shareholders (₹ 690.28 million) in proportion to the equity shares allotted to the public as fresh issue by the Holding Company and under the offer for sale by selling shareholders respectively. Out of the total IPO proceeds the funds available in public offer account is ₹ 513.14 million for remitting funds for pending IPO related expenses.  
The Holding Company has received an amount of ₹ 6,373.70 million (net of IPO expenses of ₹ 426.30 million) from proceeds out of fresh issue of equity shares. The utilisation of the net IPO proceeds is summarised below:

Objects	Planned net proceeds as per prospectus	Actual net proceeds	Utilisation upto 31 December 2024	Unutilised amount as on 31 December 2024
Repayment/prepayment of all or certain borrowings of Holding Company	1,599.10	1,599.10	1,599.10	-
Repayment/prepayment of all or certain borrowings of Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	2,270.90	-
Funding incremental working capital requirements of Holding Company	550.00	550.00	-	550.00
Pursuing inorganic growth initiatives through acquisitions	278.70	278.70	-	278.70
General corporate purposes	1,675.00	1,675.00	1,675.00	-
<b>Total proceeds</b>	<b>6,373.70</b>	<b>6,373.70</b>	<b>5,545.00</b>	<b>828.70</b>

- The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Holding Company.
- The Holding Company in earlier years, executed a shareholders' agreement (the 'Agreement') with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby QC Investments Pte. Limited (the 'Investor') wherein the Investor was given the right to require the Holding Company to buyback its equity shares at fair market value in case the Holding Company and/ or its promoters was not able facilitate exit to the Investor either through an 'initial public offer' or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the consolidated financial results of the Group which has been shown separately in the aforementioned consolidated financial results.  
However, on 29 May 2024, the Investor have waived off these rights in entirety and accordingly, the Holding Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these consolidated financial results till 29 May 2024 amounting to ₹ 38.67 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from financial liabilities to other equity.
- During the quarter ended 30 September 2023, owing to floods in Chandigarh and nearby areas, one of the group company had incurred certain damages to inventory along with property, plant and equipment at factory locations in Derra Bassi and Lalru plants amounting to ₹ 274.14 million. The management has filed necessary claims for the damages made with the insurance authorities.  
  
During the nine-month period ending 31 December 2024, following some minor repairs, few machineries were restored to working condition, and the factory building at the Lalru site was considered safe for use after a reassessment that included minor refurbishments. As a result of this reassessment, losses of ₹ 47.81 million and ₹ 84.80 million are recognized as an exceptional income for the quarter and nine months period ended 31 December 2024 respectively in the consolidated financial results.
- Subsequent to the quarter and nine-month period ended 31 December 2024, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group.  
During the search and seizure proceedings, the Group has fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Group continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. The Holding company has not yet received any written order/ notice/ communication on the findings of such investigation from the department and accordingly, there have been no demands which have been raised on the Group as of date. Based on the foregoing and having regard to the matters of the inquiry during the search proceedings stated above, management is of the view that no material adjustments are required to these unaudited consolidated financial results for the quarter and nine months period ended 31 December 2024 in this regard.
- The figures for the quarter ended 31 December 2023 are the balancing figures between the management certified year to date figures upto the nine months period ended 31 December 2023 and audited year to date figures upto six months period ended 30 September 2023 extracted from the audited Special Purpose Consolidated Interim Statement of Profit and loss for the six months period ended 30 September 2023.
- The consolidated financial results for the quarter and nine months period ended 31 December 2023 have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the consolidated financial results for this quarter and nine months provide a true and fair view of the Group's affairs.



For and on behalf of Board of Directors of  
Akums Drugs and Pharmaceuticals Limited

*Sanjeev Jain*

Sanjeev Jain  
Managing Director  
DIN: 00323433

*Sandeep Jain*

Sandeep Jain  
Managing Director  
DIN: 00323476




## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

### Annexure-B

Sr. No.	Particulars	Details
1.	Name of the Target Entity, details in brief such as size, turnover etc.	Proposed Name (or any other name):  1. Akums Healthcare UK Ltd. 2. Akums Healthcare Malta Ltd.  Details in brief as size / turnover:  Not Applicable since the company is yet to be incorporated.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed subsidiaries once incorporated will be related party of the company.  There is no interest of promoter/ promoter group/ group companies in the transaction.
3.	Industry to which the entity being acquired belongs	The proposed subsidiaries will deal in trading and marketing of pharmaceuticals formulations.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable, the proposed subsidiaries business will be in line with the business of the listed company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	The incorporation of the proposed subsidiaries shall be subject to the approvals from relevant statutory authorities.
6.	Indicative time period for completion of the acquisition	The completion of incorporation of the proposed subsidiaries shall be subject to



ISO 9001 : 2015  
 ISO 14001 : 2015  
 ISO 17025 : 2005 (NABL)


WHO-GMP  
 US : NSF  
 HACCP



## AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)  
 Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083  
 Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

		the approvals from relevant statutory authorities.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration shall be paid towards subscription of the share capital of the proposed subsidiaries.
8.	Cost of acquisition and/or the price at which the shares are acquired;	Not Applicable
9.	Percentage of shareholding / control acquired and / or number of shares acquired	100% (Wholly Owned Subsidiaries or Step-Down Subsidiaries)
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable



ISO 9001 : 2015  
 ISO 14001 : 2015  
 ISO 17025 : 2005 (NABL)

WHO-GMP  
 US : NSF  
 H A C C P

